PROSPERI DAVIDE

Barbieri, L., Salvioni, L., Banfi, A., Garbujo, S., Fiandra, L., Baioni, C., et al. (2025). Dual-Targeting Strategy to Repurpose Cetuximab with HFn Nanoconjugates for Immunotherapy of Triple-Negative Breast Cancer. ACS APPLIED MATERIALS & INTERFACES [10.1021/acsami.5c06626]. Detail

Sinesi, G., Salvioni, L., Ronchi, E., Barbuzzi, E., Prosperi, D., Colombo, M., et al. (2025). Exploring Bovine Serum Albumin (BSA) as a Facile Substrate for Testing of Osmolytes as Cosmetic Ingredients. MOLECULES, 30(3) [10.3390/molecules30030664]. Detail

Giustra, M., Sinesi, G., Spena, F., De Santes, B., Morelli, L., Barbieri, L., et al. (2024). Microplastics in Cosmetics: Open Questions and Sustainable Opportunities. CHEMSUSCHEM, 17(22 (November 25, 2024)) [10.1002/cssc.202401065]. Detail

Morelli, L., Ochoa, E., Salvioni, L., Davide Giustra, M., De Santes, B., Spena, F., et al. (2024). Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 652(5 March 2024) [10.1016/j.ijpharm.2024.123850]. Detail

Ochoa, E., Morelli, L., Salvioni, L., Giustra, M., De Santes, B., Spena, F., et al. (2024). Co-processed materials testing as excipients to produce Orally Disintegrating Tablets (ODT) using binder jet 3D-printing technology. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 194(January 2024), 85-94 [10.1016/j.ejpb.2023.11.023]. Detail